These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 7738878)
1. Pharmacovigilance: paradise lost, regained or postponed? The William Withering Lecture 1994. Rawlins MD J R Coll Physicians Lond; 1995; 29(1):41-9. PubMed ID: 7738878 [No Abstract] [Full Text] [Related]
2. Lessons from Eprex for biogeneric firms. Louët S Nat Biotechnol; 2003 Sep; 21(9):956-7. PubMed ID: 12949539 [No Abstract] [Full Text] [Related]
3. FDA seeks advice on track-and-trace systems. Traynor K Am J Health Syst Pharm; 2011 Apr; 68(7):552-4. PubMed ID: 21411794 [No Abstract] [Full Text] [Related]
4. Industry reneges on postmarketing trial commitments. Bouchie A Nat Biotechnol; 2003 Jul; 21(7):718. PubMed ID: 12833074 [No Abstract] [Full Text] [Related]
5. From pharmacovigilance to pharmacoperformance. Peachey J Drug Saf; 2002; 25(6):399-405. PubMed ID: 12071776 [TBL] [Abstract][Full Text] [Related]
6. Equivocal role of micelles in Eprex adverse events. Smiell JM Nat Biotechnol; 2003 Nov; 21(11):1265; author reply 1266. PubMed ID: 14595347 [No Abstract] [Full Text] [Related]
7. Equivocal role of micelles in Eprex adverse events. Schellekens H; Crommelin DJ Nat Biotechnol; 2003 Nov; 21(11):1265; author reply 1266. PubMed ID: 14595346 [No Abstract] [Full Text] [Related]
8. What do stakeholders think about pharmacovigilance? Edwards IR; Graedon T Drug Saf; 2010 Aug; 33(8):619-21. PubMed ID: 20635819 [No Abstract] [Full Text] [Related]
9. FDA increases focus on postmarketing studies. Goozner M J Natl Cancer Inst; 2010 Sep; 102(17):1302-4. PubMed ID: 20739650 [No Abstract] [Full Text] [Related]
10. New approaches to drug safety: a pharmacovigilance tool kit. Wise L; Parkinson J; Raine J; Breckenridge A Nat Rev Drug Discov; 2009 Oct; 8(10):779-82. PubMed ID: 19763106 [TBL] [Abstract][Full Text] [Related]
11. [Sense and nonsense of post-authorization surveillance]. de Mey C Med Klin (Munich); 2000 Jan; 95(1):56-62. PubMed ID: 10668347 [No Abstract] [Full Text] [Related]
12. What you don't know will hurt you. Nat Biotechnol; 2008 Jun; 26(6):589. PubMed ID: 18536658 [No Abstract] [Full Text] [Related]
13. Canaries, coal mines and the drug supply. Leiden JM Nat Biotechnol; 2008 Jun; 26(6):624-6. PubMed ID: 18536681 [No Abstract] [Full Text] [Related]
15. The FDA and safety--beyond the heparin crisis. Laurencin CT; Nair L Nat Biotechnol; 2008 Jun; 26(6):621-3. PubMed ID: 18536680 [No Abstract] [Full Text] [Related]
16. Approval times and the safety of new pharmaceuticals. Rudholm N Eur J Health Econ; 2004 Dec; 5(4):345-50. PubMed ID: 15452739 [TBL] [Abstract][Full Text] [Related]
17. "Safer, but not safe enough". Crombie HD Conn Med; 2006; 70(10):645. PubMed ID: 17190395 [No Abstract] [Full Text] [Related]
18. Bad medicine. Monitoring programs target substandard drugs. Grens K Mod Healthc; 2013 May; 43(20):30-1. PubMed ID: 23947275 [No Abstract] [Full Text] [Related]
19. [The need for 'postmarketing surveillance']. Stricker BH; in 't Veld BA; Feenstra J Ned Tijdschr Geneeskd; 1999 Apr; 143(14):711-3. PubMed ID: 10347624 [TBL] [Abstract][Full Text] [Related]
20. The future of pharmacovigilance: a personal view. Edwards IR Eur J Clin Pharmacol; 2008 Feb; 64(2):173-81. PubMed ID: 18172624 [No Abstract] [Full Text] [Related] [Next] [New Search]